 Proactive Investors USA & Canada |
Relovair COPD and asthma filings on track despite more mixed trial results
The Pharma Letter For asthma, the company plans to file for approval in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication. GSK is looking to replace its top-selling drug … Relovair on track for filing in mid-2012, says GSK GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, Asthma GSK and Theravance Announce Completion of the Relovair(TM)* Registrational … |
View full post on asthma – Google News